Global Long-term Outcomes and Real-World Evaluation of Dexcom Continuous Glucose Monitoring System (Dexcom GLOW)

NCT07681024 | Not Yet Recruiting FDA Device

• 1 other identifier: PTL-1000728
• Study Type: observational
• Target: 5,000
• Locations: 0 countries
• Sites: N/A

Brief Summary

Global Registry study

Conditions

Diabetes

Outcome Measures

Primary Outcomes (1)

• Evaluations

  Evaluate outcomes of CGM use for each diabetes type within a given country

  Up to 8 years

Interventions

Dexcom CGM (Continuous Glucose Monitor) DEVICE

Use Dexcom CGM according to approved commercial use. Evaluate HbA1c over time.

Also known as: Dexcom ONE, Dexcom Flex, Dexcom G7

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study intends to prioritize enrollment of participants living with Type 2 Diabetes (T2D): Intensive Insulin Therapy (IIT), Basal Insulin, and Non-Insulin Taking (NIT), participants.

You may qualify if:

• "1. Meets Dexcom CGM System Indications for Use (IFU) per approved commercial labeling
• \. Has at least one HbA1C (Hemoglobin a1c) measurement obtained within the three (3) months prior to the start date of first Dexcom CGM System use in the study (blinded or unblinded, whichever first). For participants with prior CGM experience (CGM non-naive), this HbA1c measurement must also be at least three (3) months after the end of any CGM usewithin three (3) months prior to the Dexcom CGM System use start date that is at least three (3) months after any prior CGM use
• \. Participant is willing and able to use Dexcom CGM System according to approved product labeling
• \. Participant is willing and able to complete applicable patient reported outcome assessments/ surveys
• \. Participant is willing and able to comply with the Clinical Investigation Plan
• \. Participant is willing and able to comply with provider requirements for at least one or more provider encounters after CGM initiation according to applicable clinical practice guidelines
• \. Participant or the participant's legally authorized representative must provide written informed consent prior to any study-related data collection or be enrolled under an IRB/EC/REB approved waiver of consent"

You may not qualify if:

• "1. Is contraindicated for a Dexcom CGM System per approved commercial labeling
• \. In the Investigator's opinion, the participant is not considered to be a suitable candidate
• \. Currently participating in another study and receiving and intervention study"

Sponsors & Collaborators

• DexCom, Inc.: lead

MeSH Terms

Conditions

Diabetes Mellitus

Condition Hierarchy (Ancestors)

Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases

Central Study Contacts

Margo Sedano

CONTACT

858-704-2428; margo.sedano@Dexcom.com

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 26, 2026
• First Posted: July 2, 2026
• Study Start: June 15, 2026
• Primary Completion (Estimated): May 1, 2030
• Study Completion (Estimated): May 1, 2030
• Last Updated: July 2, 2026

Record last verified: 2026-06